XML 43 R31.htm IDEA: XBRL DOCUMENT
v3.21.2

Financing (Tables) | 9 Months Ended
--- | ---
Oct. 01, 2021
Debt Disclosure [Abstract] |
Components Of Debt | The components of the Company’s debt were as follows ($ in millions):
| October 1, 2021 |  | December 31, 2020
Euro-denominated commercial paper (€1.2 billion and €500 million, respectively) | $ | 1,392 |  |  | $ | 611 |
U.S. dollar-denominated commercial paper | 2,677 |  |  | — |
Zero-coupon LYONs due 2021 | — |  |  | 24 |
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”) | — |  |  | 290 |
Floating rate senior unsecured notes due 2022 (€250 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”) | 290 |  |  | 305 |
2.05% senior notes due 2022 (the “2022 Biopharma Notes”) | 699 |  |  | 698 |
0.5% senior unsecured bonds due 2023 (CHF 540 million aggregate principal amount) (the “2023 CHF Bonds”) | 581 |  |  | 611 |
1.7% senior unsecured notes due 2024 (€900 million aggregate principal amount) (the “2024 Euronotes”) | 1,039 |  |  | 1,096 |
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”) | 697 |  |  | 697 |
2.5% senior unsecured notes due 2025 (€800 million aggregate principal amount) (the “2025 Euronotes”) | 925 |  |  | 975 |
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”) | 498 |  |  | 498 |
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”) | 1,443 |  |  | 1,520 |
2.1% senior unsecured notes due 2026 (€800 million aggregate principal amount) (the “2026 Euronotes”) | 923 |  |  | 975 |
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”) | 277 |  |  | 297 |
1.2% senior unsecured notes due 2027 (€600 million aggregate principal amount) (the “2027 Euronotes”) | 692 |  |  | 729 |
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”) | 1,440 |  |  | 1,518 |
1.125% senior unsecured bonds due 2028 (CHF 210 million aggregate principal amount) (the “2028 CHF Bonds”) | 229 |  |  | 241 |
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”) | 795 |  |  | 795 |
2.5% senior unsecured notes due 2030 (€800 million aggregate principal amount) (the “2030 Euronotes”) | 926 |  |  | 978 |
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”) | 2,018 |  |  | 2,127 |
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”) | 478 |  |  | 514 |
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”) | 1,433 |  |  | 1,511 |
3.25% senior unsecured notes due 2039 (the “2039 Biopharma Notes”) | 890 |  |  | 889 |
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”) | 499 |  |  | 499 |
1.8% senior unsecured notes due 2049 (€750 million aggregate principal amount) (the “2049 Biopharma Euronotes”) | 860 |  |  | 907 |
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”) | 889 |  |  | 889 |
2.6% senior unsecured notes due 2050 (the “2050 U.S. Notes”) | 980 |  |  | 979 |
Other | 28 |  |  | 31 |
Total debt | 23,598 |  |  | 21,204 |
Less: currently payable | 7 |  |  | 11 |
Long-term debt | $ | 23,591 |  |  | $ | 21,193 |

X
- References No definition available. + Details
Name: | us-gaap_DebtDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69E -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 + Details
Name: | us-gaap_ScheduleOfDebtInstrumentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration